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Background: The spread of multidrug-resistant tuberculosis (MDR-TB) Mycobacterium tuberculosis (M. tuberculosis)
strains has been a big challenge to the TB control and prevention in China. Knowledge about patterns of drug
resistance in TB high-burden areas of China is crucial to develop appropriate control strategies. We conducted a
comprehensive investigation of the resistance pattern of M. tuberculosis in Heilongjiang Province.
Methods: 1427M. tuberculosis clinical strains were isolated from pulmonary TB patients hospitalized between
2007 and 2012. The susceptibility of the isolates to the first-line anti-TB drugs and the resistance of MDR M.
tuberculosis to fluoroquinolones were examined. We also performed a statistical analysis to identify the correlated
risk factors for high burden of MDR-TB.
Results: The global resistance rates of 2007–2012 to the first-line drugs and MDR were 57.0 and 22.8 %, respectively.
Notably, the primary MDR-TB and pan-resistance rates were as high as 13.6 and 5.0 %, respectively. Of MDR
M. tuberculosis isolates (2009), approximately 13 % were not susceptible to any of the fluoroquinolones tested.
Being age of 35 to 54, high re-treatment proportion, the presence of cavity lesion, and high proportion of shorter
hospitalization are correlated with the development of MDR-TB.
Conclusions: The high prevalence of drug resistant, MDR-TB, and fluoroquinolone-resistant MDR-TB is a big concern
for TB control. More importantly, in order to control the development of MDR-TB effectively, we need to pay
more attention to the primary resistance. Targeting reducing the prevalence of the risk factors may lead to
better TB control in China.
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The spread of drug-resistant and multidrug-resistant
(MDR) tuberculosis (TB) is a severe global health issue.
In recent years, both the incidence and prevalence of TB
in China have steadily declined [1]. The World Health
Organization (WHO) indicates that the MDR rates in
China (5.7 % in new cases and 26 % in previously treated
cases, respectively) have become lower than in other* Correspondence: lingh@ems.hrbmu.edu.cn
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However, the rates remain higher than the global average
rates of 3.6 and 20 % for new and previously treated
cases, respectively. China is ranked second in the num-
ber of MDR-TB cases after India because of China’s large
population. Moreover, the global extensively drug-
resistant (XDR)-TB prevalence is increasing, with 9.6 %
MDR-TB cases in 2012 compared to 5.4 % in 2007. We
estimate an increasing XDR-TB prevalence in China,
with 8 % from MDR-TB cases, because this rate was
higher than the worldwide level in 2007 [1]. The global
spread of XDR-TB has led to new challenges for the pre-
vention and control of tuberculosis.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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geographic areas of China vary greatly, and recently, the
spread of TB in China has been caused by active domestic
migration, resulting in a significant public health issue.
Heilongjiang Province is located in Northeast China, a re-
gion in which the prevalence rates of both TB and drug-
resistant TB are higher than the average in China [2–4].
The rates of any resistance to first-line drugs were 38.9
and 36.2 % for new cases and 70.9 and 67.7 % for re-
treated cases in Heilongjiang Province in 2002 and 2004,
respectively, based on data from population-based drug
resistance investigations [2–4].
It is important to identify the causes for the high preva-
lence of drug-resistance TB. The risks associated with
drug resistant- and MDR-TB include a history of retreat-
ment using anti-mycobacterial drugs, having cavities,
Beijing genotype epidemic, low socio-economic status, age
and DOTS (directly observed treatment short course) im-
plementation. However, the factors vary depending on the
study [1, 5–8].
Moreover, we would like to determine whether the
prevalence of fluoroquinolone resistant TB in Heilongjiang
Province is also high. MDR-TB is a risk factor for the re-
sistance of M. tuberculosis to fluoroquinolones [9, 10]. In
China, fluoroquinolones are the most frequently used anti-
biotics for the treatment of a variety of infectious diseases
[11–14]. XDR-TB arises when MDR-TB strains acquire re-
sistance to any fluoroquinolone, and previous treatment
using second-line drugs, including fluoroquinolones, is a
significant risk factor for XDR-TB [15, 16].
In the present study, we analyzed the resistance trends
of M. tuberculosis clinical isolates from 2007 to 2012 to
first-line drugs and fluoroquinolones and the risk factors
in Heilongjiang Province, an area with the highest tuber-
culosis disease and drug resistance burden in China. Elu-
cidating the locally significant risk factors for the high
prevalence of TB is important to control the spread of
TB and drug resistant TB in this area and other regions
of China.
Methods
Mycobacterial specimen and data collection
All the data we collected including patient medical re-
cords are available in Harbin Chest Hospital. A total of
1427 isolates from 1427 patients, who were diagnosed
with TB at the Harbin Chest Hospital from May 2007
and July 2012 and from various regions of Heilongjiang
Province, were included. The patients were HIV-1 nega-
tive. The patient information of gender, age, TB treatment
history, and the presence of cavity on chest radiographs
was from hospital medical records. Ethical clearance and
approval for this study was provided by the Institutional
Research Board of the University of Harbin Medical
University (Ethics Reference No.: HMUIRB20160001).Mycobacterial culture and drug susceptibility testing
(DST) to first-line drugs
Mycobacterial cultures were obtained from clinical speci-
mens after incubation in a BACTEC Mycobacterium
Growth Indicator Tube (MGIT) 960 Automated System
(BD Diagnostic Systems, Franklin Lakes, NJ, USA). Pri-
mary identification was performed using the Ziehl-Neelsen
staining method and microscopy. The tests of inhibition by
P-nitrobenzoic acid and 2-Thiophenecarboxylic acid hydra-
zide were used to differentiate M. tuberculosis from other
Mycobacterium spp. DST to first-line drugs was performed
using MGIT 960 SIRE Kit. Strict controls including growth
control (M. tuberculosis H37Rv growth control in drug-
free tube) and the negative control (H37Rv in the presence
of each drug) were used according to the instruction of
MGIT 960 SIRE Kit.
The resistance of MDR M. tuberculosis to fluoroquinolones
Resistance of some MDR isolates from 2009 to 2012 to
FQs was examined in the Hospital as clinical departments
suggested. The susceptibility of the MDR strains isolated
in 2009 (n = 52, recovered from the frozen stock) to FQs
including levofloxacin (Sigma), sparfloxacin (Sigma), mox-
ifloxacin (Hubei Saibo Pharmaceutical company, Wuhan,
China), gemifloxacin (Hubei Saibo Pharmaceutical com-
pany, Wuhan, China), and gatifloxacin (National Institutes
for Food and Drug Control, Beijing, China) was examined
by minimun inhibition concentrations (MIC) assay. The
test was performed using the standard microdilution
method as described previously [17]. Initial concentration
was 16 mg/L for both levofloxacin and sparfloxacin, and
8 mg/L for moxifloxacin, gemifloxacin, and gatifloxacin.
Seven serial two-fold dilutions of each drug in Middleb-
rook 7H9 were performed [18–20]. Each well was inocu-
lated with a 0.03 McFarland mycobacterial suspension
(final inoculums was 2.85 × 105 CFU/mL). Two wells
without drugs were inoculated with H37Rv as a growth
control. All peripheral wells of the plates were filled with
sterile distilled water. The plates were incubated at 37 °C
for 16 to 18 days. For each drug, the lowest concentration
that displayed no visible turbidity was defined as the MIC.
Three independent assays were performed.
The susceptibility of MDR isolates from 2010 to 2012
to levofloxacin was determined by using absolute con-
centration method on solid Lowenstein-Jensen medium
(Hangzhou Genesis Biodetection & Biocontrol Ltd) upon
National Guideline. The concentration of 2 mg/L was
set as the breakpoint [21].
DNA extraction, PCR-based identification of M. tuberculosis,
and Beijing genotype determination
Bacterial DNA was extracted after the inactivation of
mycobacterial isolates in 70 % ethanol for 2 h [22]. DNA
was extracted using lysozyme and the phenol-chloroform
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with the PCR amplifications of the genes including 16S
rRNA, Rv0577, Rv2073c, and Rv3120 was performed as
previously described [24, 25]. M. tuberculosis strains have
positive amplifications of the four genes. M. microti and
M. tuberculosis H37Rv was used as reference strains.
To identify the Beijing genotype of the isolates,
RD105 deletion PCR was performed as described pre-
viously [24].Statistical analysis
The odds ratio was used to evaluate the univariate and
multivariate risk factors associated with MDR-TB and
drug resistant- (not MDR) TB. The following variables
were included in the analysis: the patient’s gender, age,
TB treatment history, presence of a cavity on chest
radiograph, hospitalization time and Beijing genotype.
All of the variables were initially included in the model,
and the forward method was used to select the final vari-
ables. The statistical interaction between relevant variables
was assessed. All statistical analyses were performed using
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).Table 1 Susceptibility of the M .tuberculosis isolated in Heilongjiang
Characteristics 2007 2008 2009
No. % No. % No. %
All 198 348 275
Any drug resistance 110 55.6 209 60.1 189 68.7
RPF or INHa,b 42 21.2 77 22.1 72 26.2
SM 72 36.4 152 43.7 125 45.5
EMB 47 23.7 74 21.3 75 27.3
MDR 44 22.2 90 25.9 81 29.5
Pan-resistancec 21 10.6 49 14.1 37 13.5
From new cases 126 218 171
Any drug resistance 62 49.2 113 51.8 103 60.2
RPF or INH 24 19.0 43 19.7 46 26.9
SM 42 33.3 84 38.5 67 39.2
EMB 19 15.1 32 14.7 38 22.2
MDR 20 15.9 36 16.5 29 17.0
Pan-resistance 5 4.0 17 7.8 14 8.2
From re-treated cases 72 130 104
Any drug resistance 48 66.7 96 73.8 86 82.7
RPF or INH 18 25.0 34 26.2 26 25.0
SM 30 41.7 68 52.3 58 55.8
EMB 28 38.9 42 32.3 37 35.6
MDR 24 33.3 54 41.5 52 50.0
Pan-resistance 16 22.2 32 24.6 23 22.1
aINH isoniazid, RFP rifampicin, MDR multidrug-resistance, SM streptomycin, EMB eth
bThe isolates were resistant to RPF or INH but not both
cThe isolates were resistant to all the four first-line drugResults
Sample and data collection
Of the 1427 patients with pulmonary tuberculosis identi-
fied from May 2007 through July 2012, 918 (64.3 %) and
509 (35.7 %) were new and re-treated cases, respectively
(Table 1). The medical records were available for all
cases. Chest radiographs indicating the presence or ab-
sence of cavity were available for 1254 cases. Three hun-
dred isolates from May 2007 through September 2009
were re-confirmed by PCR-based identification and were
further examined to identify the Beijing family genotype
and phylogeny based on the VNTR genotypes. Fifty two
re-cultured available MDR M. tuberculosis isolates from
2009 were examined for sensitivity to fluoroquinolones
(MIC). The susceptibility of MDR isolates from 2010 to
2012 to levofloxacin was available from routine clinical
drug resistance examinations in hospital.
High prevalence of drug-resistant TB in Heilongjiang
Province from 2007 to 2012
Overall, the average resistance rate of TB to any first-
line drugs from 2007 to 2012 was 57.0 % (Table 1). The
drug resistance rate among new case and re-treated caseProvince to the first-line anti-tuberculosis drugs
2010 2011 2012 Total
No. % No. % No. % No. %
204 205 197 1427
121 59.3 89 43.4 96 48.7 814 57.0
55 27.0 42 20.5 40 20.3 328 23.0
86 42.2 63 30.7 63 32.0 561 39.3
16 7.8 17 8.3 18 9.1 247 17.3
39 19.1 33 16.1 38 19.3 325 22.8
10 4.9 12 5.9 11 5.6 140 9.8
143 136 124 918
74 51.7 46 33.8 49 39.5 447 48.7
37 25.9 24 17.6 23 18.5 197 21.5
53 37.1 32 23.5 31 25.0 309 33.7
9 6.3 6 4.4 5 4.0 109 11.9
18 12.6 11 8.1 11 8.9 125 13.6
4 2.8 4 2.9 2 1.6 46 5.0
61 69 73 509
47 77.0 43 62.3 47 64.4 367 72.1
18 29.5 18 26.1 17 23.3 131 25.7
33 54.1 31 44.9 32 43.8 252 49.5
7 11.5 11 15.9 13 17.8 138 27.1
21 34.4 22 31.9 27 37.0 200 39.3
6 9.8 8 11.6 9 12.3 94 18.5
ambutol
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was 22.8 %. Of the MDR cases, 13.6 and 39.3 % were
new and re-treated cases, respectively. The highest
prevalence of resistance to the first-line drugs and MDR
from either the new or retreated cases occurred in 2009
and the lowest occurred in 2011 (Table 1).
There was also a high prevalence of primary resistance
(Table 1). Of the cases resistant to any first-line drug and
MDR-TB cases, approximately 55 and 39 %, respectively,
were new cases. From 2007 to 2012, the yearly resistance
to any first-line drug among new cases, was 49.2, 51.8,
60.2, 51.7, 33.8, and 39.5 %, respectively. The MDR rates
were 15.9, 16.5, 17.0, 12.6, 8.1, and 8.9 %, respectively.
Notably, 5.0 % of the pan-resistant cases (resistant to all 4
first-line drugs) were detected in the new cases.
Importantly, the resistance of the re-treated cases was
significant (Table 1). Of the cases resistant to any of the
first-line drugs and MDR-TB cases, approximately 45.1
and 61.5 %, respectively, were re-treated cases. From
2007 to 2012, the resistance rates of the re-treated cases
to any first-line drug were 66.7, 73.8, 82.7, 77.0, 62.3,
and 64.4 %, respectively. The annual rates of MDR were
33.3, 41.5, 50.0, 34.4, 31.9, and 37 %, respectively. Of the
re-treated cases, 18.5 % were pan-resistant.
The resistance of MDR M. tuberculosis isolates to
fluoroquinolones
Because the resistance rate to the first-line drugs in 2009
was the highest, resistance to fluoroquinolones of some
MDR isolates (MIC) was conducted upon suggestion of
clinical departments in strengthening the efficacy of treat-
ment (Table 2). The critical concentration for levofloxacin
is 2.0 mg/L, as per the World Health Organization, and
was used to categorize the isolates as susceptible or non-
susceptible. Because there are no recommended critical
concentrations for sparfloxacin, moxifloxacin, gatifloxacinTable 2 Susceptibilities of MDR M. tuberculosis isolates of 2009 to flu
MIC (mg/L) Levofloxacin Moxifloxacin
No. % No. %
≤0.125
≤0.25 7 13.4 5 9.6
0.50 10 19.2 18 34.6
1 mg/L 15 28.8 15 28.8
2.00 8 15.4 9 17.3
4.00 8 15.4 3 5.8
8.00 4 7.7 2 3.8
16.00
MIC ≥ 2 mg/L 20 38.5 14 26.9
MIC50b 1.0 1.0
aMDR multidrug resistance, MIC minimum inhibitory concentration
bMIC50, minimum inhibitory concentration required to inhibit the growth of 50 % oand gemifloxacin, we further analyzed the proportion of
isolates with MICs equal to and higher than 2 mg/L, based
on the serum concentrations of the drugs [20], and they
were defined as non-sensitive to a drug.
Of the MDR isolates, 36.5, 26.9, 38.4, and 40.4 % were
not susceptible to sparfloxacin, moxifloxacin, gemifloxacin
and gatifloxacin, respectively. We also found that there
were high proportions of MDR M. tuberculosis isolates re-
sistant to the fluoroquinolones (Table 3). Approximately
21 % of the isolates were not susceptible to levofloxacin
and moxifloxacin. The resistance rates to the 3rd and 4th
generation of fluoroquinolones were 15.4–17.3 % and
13.5–15.4 %, respectively. Notably, 13.5 % of the isolates
were not susceptible to 5 fluoroquinolones.
We also analyzed the results of the susceptibility test
of M. tuberculosis to levofloxacin that was available since
2010. We found that 22.6 % (7/31), 27.6 % (8/29), and
25 % (9/36) MDR isolates from 2010, 2011, and 2012, re-
spectively, were resistant to levofloxacin.Factors linked to drug-resistant TB
The risk factors associated with drug resistance were an-
alyzed (Table 4). We found that an age of 35 to 54 (OR
2.5, 95 % CI 1.8–3.4), re-treatment history (OR 5.3, 95 %
CI 4.0–7.1), the presence of cavity (OR 1.8, 95 % CI 1.3–
2.5), shorter hospitalization (OR 6.4, 95 % CI 4.8–8.7),
and infection with the Beijing genotype (OR 4.3, 95 % CI
1.2–15.1) were high-risk factors for the development of
MDR-TB based on the univariate analysis. The multi-
variate analysis further confirmed these findings, except
that the Beijing genotype was not included in the final
logistic-regression models [26].
Furthermore, MDR-TB cases had a higher frequency
(61.5 %) of re-treatment compared to the drug resistant-
TB cases (34.2 %). Of the MDR cases, 60.3 % had non-oroquinolonesa
Sparfloxacin Gemifloxacin Gatifloxacin
No. % No. % No. %
2 3.8 1 1.9
14 26.9 7 13.5 8 15.4
9 17.3 14 26.9 15 28.8
10 19.2 9 17.3 7 13.5
8 15.4 14 26.9 12 23.1
7 13.5 6 11.5 7 13.5
3 5.8 2 3.8
1 1.9
19 36.5 20 38.4 21 40.4
1.0 1.0 1.0
f examining clinical isolates
Table 3 Multiple resistance of MDR-Mtb isolates of 2009 to
FQs (n = 52)a
Category MIC < 2 mg/L MIC ≥ 2 mg/L
No. % No. %
Lfx + Mfx 29 55.8 11 21.2
Lfx + Mfx + Gfx 24 46.2 8 15.4
Lfx + Mfx + Gmx 27 51.9 9 17.3
Lfx + Mfx + Sfx 26 50.0 8 15.4
Lfx + Mfx + Sfx + Gmx 25 48.1 8 15.4
Lfx + Mfx + Gfx + Gmx 24 46.2 7 13.5
Lfx + Mfx + Gfx + Sfx 24 46.2 7 13.5
Lfx + Mfx + Gfx + Sfx + Gmx 24 46.2 7 13.5
aMDR multidrug resistance, Mtb M. tuberculosis, FQs fluoroquinolones, MIC
minimum inhibitory concentration, Lfx levofloxacin, Sfx sparfloxacin, Mfx
moxifloxacin, Gmx gemifloxacin, Gfx gatifloxacin
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drug resistant-TB cases.
Overall, the proportion of cases with cavity, aged 35 to
54, and re-treatment history were 64.8, 41.1, and 35.7 %,
respectively, in the TB patients from the study areaTable 4 Univariate and multivariate analysis of risk factors for drug-r










Male 994(69.7) 425 (69.3) 343(70.1) 226 (69.5
Female 433(30.3) 188 (30.7) 146(29.9) 99 (30.5)
Age group, y
7–34 469(32.9) 234(38.2) 152(31.1) 83 (25.5)
35–54 587(41.1) 198 (32.3) 215(44.0) 174 (53.5
≥ 55 371(26.0) 181 (29.5) 122(24.9) 68 (20.9)
History of TB treatment
No 918(64.1) 471 (76.8) 322(65.8) 125 (38.5
Yes 509(35.7) 142(23.2) 167(34.2) 200 (61.5
Cavity visible on radiographb
No 442(35.2) 222 (39.8) 147(34.9) 73 (26.5)
Yes 812(64.8) 336 (60.2) 274(65.1) 202 (73.5
With standard hospitalization
Yes 1021(71.5) 496 (80.9) 396 (81.0) 129 (39.7
Noc 406(28.5) 117 (19.1) 93(19.0) 196 (60.3
Beijing genotyped
No 31(10.3) 17 (14.8) 11 (10.2) 3 (3.9)
Yes 269(89.7) 98 (85.2) 97 (89.8) 74 (96.1)
aMDR multidrug resistance, OR odds ratio, CI confidence interval, NA not applicable
logistic-regression models)
bThe radiograph results were available with 1254 patients during the period 2007 t
cThe hospitalization days of the cases were shorter than the required by the Nation
retreated and MDR cases, respectively [26]
dBeijing genotype analysis with 300 isolates from 2007 to 2009 was available(Table 4). In this region, the Beijing genotype prevalence
was 89.7 %. However, the proportion of cases with non-
standard hospitalization was 28.5 %.
Discussion
Heilongjiang Province is an area of China with high bur-
dens of drug resistant- and MDR-TB [2–4]. However,
the reported resistance rates were based on data from
the China CDC system. In China, the CDC system gen-
erally takes care of outpatients, whereas TB hospitals
accept either outpatients or inpatients. The complicated
TB cases are usually admitted to TB hospitals. Nation-
wide studies have shown that first line drug resistance
and MDR rates are different among different geograph-
ical areas and patient population [1, 10, 27–46] (Table 5).
The resistance rates of clinical isolates from 2007 to
2014 to first-line drugs were higher in hospitalized pa-
tients [10, 31, 34, 38, 39, 42–44]. On the other hand,
surveys based on wide range of TB cases (including out-
patients and inpatients) exhibited comparatively lower
resistance rates [29, 30, 32, 37]. The MDR prevalence
showed similar trend [10, 29–32, 34–46].esistant (not MDR) and MDR TBa
Drug-resistant vs. Pan-sensitive
OR (95 % CI)
MDR vs. Pan-sensitive










) Referent NA Referent NA
1.0 (0.8–1.3) NA 1.0 (0.7–1.4) NA
Referent Referent Referent Referent
) 1.7 (1.3–2.2) 1.5 (1.1–2.0) 2.5 (1. 8–3.4) 1.7 (1.2–2.5)
1.0 (0.8–1.4) 0.9 (0.7–1.2) 1.0 (0.7, 1.5) 0.6 (0.4–0.9)
) Referent Referent Referent Reference
) 1.7 (1.3–2.2) 1.7 (1.2–2.1) 5.3 (4.0–7.1) 3.6 (2.6–5.0)
Referent Referent Referent Referent
) 1.2 (0.9–1.6) 1.2 (0.9–1.6) 1.8 (1.3–2.5) 1.6 (1.0–2.2)
) Referent NA Referent Referent
) 1.0 (0.7–1.3) NA 6.4 (4.8–8.7) 5.0 (3.6–7.0)
Referent NA Referent NA
1.5 (0.7–3.4) NA 4.3 (1.2–15.1) NA
(These variables were not included in the multivariate
hrough 2012
al guidelines: 21–28, 28–35 and 42–56 days for non-MDR new, non-MDR







First-line Resistance (%) MDR rate (%) FQ Resistance (%)c
Total New Total New Total MDR
China [1, 27, 28] 2007 Survey 3929 38.3 34.2 10.2 5.7
2007–2008 Survey 3634 9.9 4.0
2005–2012 Hospital 450 54.4 44.7 25.8 14.5
Jilin [29] 2008–2011 Survey 1772 40.1 33.1 13.5 8.60
Ningxia [30] 2013–2014 Survey 665 26.6 20.2 7.8
Chongqing [31] 2009–2013 Hospital 2271 61.9 52.9 26.3 16.7
Lianyungang, Jiangsu [32] 2011–2012 Survey 1012 30.4 23.4 8.7 4.2
Kaohsiung, Taiwan [33] 2000–2008 Hospital 421 15.2 2.1
Beijing [34] 2007–2009 Hospital 967 70.1 60.9 19.4 14.9 27.1 35.1
Xinjiang [35, 36] 2009–2013 Hospital 410 13.2 12.9
Heilongjiang (present) 2007–2012 Hospital 1427 57.0 48.7 22.8 13.6
2007–2009 Hospital 821 61.9 60.0 26.2 16.5
2010–2012 Hospital 606 50.5 41.9 18.2 9.9 10.4 25.0
Kunming, Yunnan [37] 2008–2009 CDC 279 31.5 9.3
Hunan [38] 2009–2010 Hospital 171 40.9 19.6 25.2 6.2 10.5
Xuzhou, Jiangsu [39] 2011–2012 Hospital 287 16.0 3.14
Zhejiang [40] 2011–2012 Hospital 1363 16.7
Rural China [10] 2008 Hospital 380 31.1 25.9 11.3 9.0 10.8 23.3
Jiangxi [41] 2010–2011 Hospital 804 19.8
Northeast China [42] 2010–2011 Hospital 205 26.3 22.0 6.8 3.0
Anhui [43] 2010–2011 Hospital 420 29.1 17.1 14.5 6.8 13.3 14.8
Shenzhen [44] 2009 Hospital 589 38.0 9.3 6.8 47.3
Chongqing [45] 2011–2013 Hospital 1976 10.5 24.5
Fujian [46] 2010–2011 Survey 1389 5.4 2.3 25.3
aMtb M. tuberculosis, MDR multidrug resistance, CDC Chinese Centre for Disease Control and Prevention, FQs fluoroquinolones
bData was derived based on sampling sources of hospital (Hospital), local TB control system (CDC) or nationwide random survey
cThe data presented the resistance rate of FQ-resistant from total or from MDR Mtb isolates examined (resistant to Ofloxacin, in Italian; resistant to
levofloxacin, underlined)
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nated TB hospital in Heilongjiang Province from 2007
through 2012, with rates of any first-line drug resistance
and MDR-TB of 57.0 and 22.8 %, respectively, whereas
these rates were 48.7 and 19.3 %, respectively, in 2012.
The rate of drug resistance in this area was highest in
2009 and decreased in 2010 and later. In the investigated
hospital, the DST availability was lower than 20 % before
2009, when DST was performed only if patients suffer
treatment failure or no obvious effect of treatment. Since
2010, DST became more frequent for culture-positive
TB patients. The increased proportion of DST might be
the reason for the decrease of drug resistance rates from
2009 to 2010. However, DST is still in only about 50 %
of the culture-positive TB cases now. This inadequate
DST availability may maintain the comparatively high
prevalence of MDR TB.
Primary resistance in this area is also an important issue.
Of the new cases investigated in 2012, approximately 40 %were resistant to any first-line drug, whereas 18.5 % were
resistant to either isoniazid or rifampin, a population at
risk of developing MDR, and 8.9 % were MDR-TB. Not-
ably, approximately 2 % of new cases were resistant to all
of the 4 first-line drugs (pan-resistance). This TB popula-
tion is the potential resource of the XDR-TB if the treat-
ment strategy is not appropriate. Regarding China’s TB
treatment regulations [26, 48], all new pulmonary TB
cases are treated free of charge with first-line drugs if DST
is not available.
Furthermore, less than 20 % of the TB medical facil-
ities that use second-line drugs for MDR-TB treatment
design therapy regimens based on DST [34]. This situ-
ation will cause the appearance of additional MDR and
XDR M. tuberculosis cases.
In the new cases, high proportions with cavity (ap-
proximately 60 %) and short hospitalization (19 %)
should also be identified. These patients are released
from hospitals after the initial treatment and may be
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individuals, causing the spread of both TB and MDR
TB. It is important to decrease the proportion of
non-standard hospitalization and appropriately treat
the cases with cavity to achieve the successful control
of primary TB spread.
The resistance situation to FQs distributed variously in
different TB populations (outpatients and inpatients)
and in different areas of China, with a higher resistance
rate in hospitalized patients. In addition, the MDR
strains would be more likely to resistant to FQs [10, 34,
38, 43–47].
In recent years, levofloxacin, the most frequently used
fluoroquinolone in China, has become the first choice
fluoroquinolone for MDR-TB treatment, and moxifloxa-
cin is used as an alternative fluoroquinolone based on
China’s clinical practice guidelines for TB [26].
Based on the present data, there is a limited choice of
fluoroquinolones for the ideal regimen for MDR-TB
therapy because approximately 15–17 % and 14–15 %
of the MDR-TB cases are not susceptible to the 3 and 4
of fluoroquinolones, respectively. Importantly, at least
13 % of the MDR M. tuberculosis isolates were not sus-
ceptible to any of the 5 fluoroquinolones. The high
prevalence of drug resistance may become uncontrolled
if measures are not effective and may indicate an in-
crease of XDR-TB.
MDR is an independent risk factor associated with re-
sistance to fluoroquinolones [9]. The high rate of MDR-
TB in the investigated area (22.8 %) is a related causative
reason for the high prevalence of fluoroquinolone resist-
ance. Furthermore, the fluoroquinolones are commonly
used antibiotics for clinical departments, and antibiotics
abuse has not been well controlled in China [11–14].
Controlling the resistance to fluoroquinolones may be
achieved through the proper management of MDR-TB
cases and the proper use of such antibiotics.
Conclusions
The results of our study indicate that there was a high
prevalence of drug resistance to the first-line drugs and
multidrug resistance (MDR) in Heilongjiang Province,
northeastern China. Among MDR TB, more than 10 %
was resistant to fluoroquinolones, indicating a severe
second line drug resistance. After analysis of the risks of
MDR-TB, we should pay more attention to patients’ age,
re-treatment proportion, cavity lesion, and high propor-
tion of shorter hospitalization to get control tuberculosis
more efficiently.
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